Oxler Private Wealth LLC Lowers Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Oxler Private Wealth LLC cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,695 shares of the company’s stock after selling 30 shares during the quarter. Oxler Private Wealth LLC’s holdings in IDEXX Laboratories were worth $826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fiduciary Group LLC purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $215,000. Van ECK Associates Corp lifted its position in IDEXX Laboratories by 16.5% in the 4th quarter. Van ECK Associates Corp now owns 16,293 shares of the company’s stock worth $9,043,000 after buying an additional 2,306 shares during the last quarter. Kestra Private Wealth Services LLC boosted its stake in IDEXX Laboratories by 3.0% in the fourth quarter. Kestra Private Wealth Services LLC now owns 799 shares of the company’s stock worth $443,000 after buying an additional 23 shares in the last quarter. Penobscot Investment Management Company Inc. grew its position in IDEXX Laboratories by 15.0% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 1,230 shares of the company’s stock valued at $683,000 after acquiring an additional 160 shares during the last quarter. Finally, WealthTrust Axiom LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $231,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 1.2 %

Shares of IDEXX Laboratories stock traded down $5.95 during trading on Friday, hitting $481.33. The company’s stock had a trading volume of 406,337 shares, compared to its average volume of 482,013. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The company has a market capitalization of $39.75 billion, a PE ratio of 46.60, a P/E/G ratio of 3.91 and a beta of 1.32. The company has a fifty day simple moving average of $481.86 and a two-hundred day simple moving average of $507.82. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business posted $2.67 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.4% on a year-over-year basis. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price for the company. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. Finally, Barclays dropped their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.